Bioline Rx Stock Beta
| BLRX Stock | ILS 8.10 0.10 1.25% |
BioLine RX fundamentals help investors to digest information that contributes to BioLine RX's financial success or failures. It also enables traders to predict the movement of BioLine Stock. The fundamental analysis module provides a way to measure BioLine RX's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to BioLine RX stock.
BioLine |
BioLine RX Company Beta Analysis
BioLine RX's Beta is one of the most important measures of equity market volatility. Beta can be thought of as asset elasticity or sensitivity to market. In other words, it is a number that shows the relationship of an equity instrument to the financial market in which this instrument is traded. For example, if Beta of equity is 2, it is expected to significantly outperform market when the market is going up and significantly underperform when the market is going down. Similarly, Beta of 1 indicates that an asset and market will generate similar returns over time.
Current BioLine RX Beta | 1.27 |
Most of BioLine RX's fundamental indicators, such as Beta, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, BioLine RX is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
In a nutshell, Beta is a measure of individual stock risk relative to the overall volatility of the stock market. and is calculated based on very sound finance theory - Capital Assets Pricing Model (CAPM).However, since Beta is calculated based on historical price movements it may not predict how a firm's stock is going to perform in the future.
| Competition |
In accordance with the recently published financial statements, BioLine RX has a Beta of 1.2675. This is 47.38% higher than that of the Biotechnology sector and 8.81% lower than that of the Health Care industry. The beta for all Israel stocks is notably lower than that of the firm.
BioLine Beta Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses BioLine RX's direct or indirect competition against its Beta to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of BioLine RX could also be used in its relative valuation, which is a method of valuing BioLine RX by comparing valuation metrics of similar companies.BioLine RX is currently under evaluation in beta category among its peers.
As the market goes up, the company is expected to outperform it. However, if the market returns are negative, BioLine RX will likely underperform.
BioLine Fundamentals
| Return On Equity | -0.37 | |||
| Return On Asset | -0.2 | |||
| Current Valuation | (13.02 M) | |||
| Shares Outstanding | 922.87 M | |||
| Shares Owned By Insiders | 0.25 % | |||
| Shares Owned By Institutions | 0.10 % | |||
| Price To Book | 0.77 X | |||
| EBITDA | (25.37 M) | |||
| Net Income | (27.05 M) | |||
| Cash And Equivalents | 40.61 M | |||
| Cash Per Share | 0.28 X | |||
| Total Debt | 10.69 M | |||
| Debt To Equity | 23.20 % | |||
| Current Ratio | 5.12 X | |||
| Book Value Per Share | 0.08 X | |||
| Cash Flow From Operations | (23.57 M) | |||
| Earnings Per Share | (0.03) X | |||
| Target Price | 3.0 | |||
| Number Of Employees | 38 | |||
| Beta | 1.27 | |||
| Market Capitalization | 135.72 M | |||
| Total Asset | 81.39 M | |||
| Retained Earnings | (163 M) | |||
| Working Capital | 43 M | |||
| Current Asset | 46 M | |||
| Current Liabilities | 3 M | |||
| Z Score | 4.4 | |||
| Net Asset | 81.39 M |
About BioLine RX Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze BioLine RX's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of BioLine RX using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of BioLine RX based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Other Information on Investing in BioLine Stock
BioLine RX financial ratios help investors to determine whether BioLine Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in BioLine with respect to the benefits of owning BioLine RX security.